Huntington, WV, United States of America

Zijian Xie

This inventor holds 9 USPTO granted patents and 3 published patent applications, plus 2 CIPO patents and 5 EPO patents. Top assignees: Marshall University Research Corporation, The University of Toledo. Active years: 2012-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Zijian Xie. Retrieved from https://idiyas.com/inventor/zijian-xie

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 9 (Patent Applications = 3)

% Patents Active = 100.0

CIPO Patents = 2 (Patent Applications = 4)

EPO Patents = 5 (Patent Applications = 8)

Average Co-Inventor Count = 2.8

ph-index = 1

Forward Citations = 8(Granted Patents)

Location History:

Saline, MI (US) (2012 - 2022)
Huntington, WV (US) (2020 - 2024)

Company Filing History:

7 out of 32

Marshall University Research Corporation

patents

2 out of 369

The University of Toledo

patents

Years Active: 2012-2024

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11958915 - Methods for treatment and diagnosis of non-alcoholic steatohepatitis and/or hepatocellular carcinoma (2024-04-16),

2. 11865162 - Compositions and methods for treatment of uremic cardiomyopathy (2024-01-09),

3. 11846638 - Methods for detecting Na/K-ATPase-mediated Src signaling for diagnosis and prognosis of cancer (2023-12-19),

4. 11311600 - Methods for treating obesity (2022-04-26),

5. 11220528 - Compositions and methods for treating pulmonary hypertension (2022-01-11),

6. 10973867 - Compositions and methods for treating retinopathy (2021-04-13),

7. 10781431 - Cardiotonic steroid antagonists and related methods (2020-09-22),

8. 8906891 - Na/K-ATPase ligand (2014-12-09),

9. 8283441 - Na+K+-ATPase-specific peptide inhibitors/activators of SRC and SRC family kinases (2012-10-09),

Title: Innovations and Contributions of Inventor Zijian Xie

Introduction

Zijian Xie is a notable inventor based in Huntington, WV, with a significant portfolio of nine patents. His work primarily focuses on medical treatments and diagnostics, particularly in the fields of liver diseases and cardiomyopathy. His innovative approaches have the potential to greatly impact patient care and treatment outcomes.

Latest Patents

Zijian Xie's latest patents include groundbreaking methods for the treatment and diagnosis of non-alcoholic steatohepatitis and hepatocellular carcinoma. These methods involve administering a polypeptide antagonist of a Na/K ATPase/Src receptor complex to patients in need. Additionally, his patents provide methods and assays for diagnosing or prognosing these conditions by analyzing biomarkers such as Caveolin-1, Survivin, and SMAC in biological samples. Another significant patent addresses the treatment of uremic cardiomyopathy, which also utilizes a polypeptide antagonist and includes methods for treating anemia associated with chronic kidney disease.

Career Highlights

Throughout his career, Zijian Xie has worked with esteemed institutions such as Marshall University Research Corporation and the University of Toledo. His contributions to research and development in the medical field have been recognized and valued, showcasing his commitment to advancing healthcare solutions.

Collaborations

Zijian Xie has collaborated with notable colleagues, including Joseph I. Shapiro and Moumita Banerjee. These partnerships have fostered a collaborative environment that enhances innovation and research outcomes.

Conclusion

Zijian Xie's contributions to medical innovation through his patents and collaborations highlight his dedication to improving treatment options for serious health conditions. His work continues to pave the way for advancements in medical science and patient care.

Profile summary based on public USPTO records.